Biotech News

ALX Oncology Reports Third Quarter 2026 Financial Results and Provides Corporate Update

ALX Oncology (ALXO)ALX OncologyEarnings

Expect to report safety and early efficacy data from the Phase 1 dose-escalation study of ALX2004 in EGFR-expressing solid tumors and plan to host a KOL webinar to review the results in December 2026 Topline data from 120 patients in Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in

Related news

ALX Oncology

CD47-Directed Immuno-Oncology ALX Oncology develops therapies intended to activate innate and adaptive antitumor immunity. Its lead approach blocks CD47 signaling while seeking to avoid broad binding to healthy cells. Evorpacept Evorpacept is a high-affinity CD47 blocker designed for combination with tumor-targeting antibodies and other...

Recent company news

Stock data

Close
1.02 USD
Market cap
239.52M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States